Sanofi Pasteur and Institut Pasteur Team up Against Malaria

    LYON, France, Oct. 15 /CNW/ - Sanofi Pasteur, the vaccines division of
sanofi-aventis Group, announced today a partnership with Institut Pasteur to
develop a vaccine against malaria. Under this collaboration agreement, Sanofi
Pasteur will have access to antigens identified by Institut Pasteur derived
from Plasmodium falciparum, the parasite responsible for the most deadly
malaria infections. Sanofi Pasteur intends to use these antigens with the goal
of developing a safe and efficacious candidate vaccine against malaria.
    "Sanofi Pasteur is committed to making malaria a vaccine-preventable
disease, ultimately relieving affected populations from this scourge," said
Wayne Pisano, President and Chief Executive Officer of Sanofi Pasteur. "Sanofi
Pasteur is continuously exploring new paths to develop innovative vaccines and
this agreement with Institut Pasteur underlines the company's historical
involvement in public-private partnerships with renowned institutions to help
improve public health."
    The World Health Organization estimates that approximately 40% of the
world's population, mostly those living in the world's poorest countries, are
at risk of malaria. Every year, more than 500 million people become severely
ill with malaria. Of those, more than one million people die every year -
mostly infants, young children and pregnant women - the majority of which are
in Africa, specifically, sub-Saharan Africa.
    "Institut Pasteur has discovered several promising antigens over the last
decade that we believe could lead to malaria vaccines to protect children
living in endemic regions as well as travellers," said Pr. Alice Dautry,
President of Institut Pasteur. "Teaming with Sanofi Pasteur, a long-standing
partner of the institute, increases the potential to reach the shared goal of
a malaria vaccine. Through this agreement, Institut Pasteur and Sanofi Pasteur
reinforce their collaboration to benefit public health."
    Sanofi Pasteur's malaria vaccine project is currently in the preclinical
phase and is expected to benefit from a network of partnerships.

    About sanofi-aventis

    sanofi-aventis, a leading global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York
    Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided
more than a billion doses of vaccine in 2006, making it possible to immunize
more than 500 million people across the globe. A world leader in the vaccine
industry, Sanofi Pasteur offers the broadest range of vaccines protecting
against 20 infectious diseases. The Company's heritage, to create vaccines
that protect life, dates back more than a century. Sanofi Pasteur is the
largest company entirely dedicated to vaccines. Every day, the company invests
more than EUR1 million in research and development. For more information,
please visit: or

    About Institut Pasteur

    Institut Pasteur, a private non-profit foundation, is dedicated to the
prevention and treatment of diseases through research, education and public
health activities. A large part of Institut Pasteur's research activities are
devoted to infectious diseases. Since it was set up, Institut Pasteur has
played a major role in combating diseases such as rabies, plague, diphtheria,
tetanus, typhus, tuberculosis, hepatitis B and AIDS. Institut Pasteur is the
heart of an International Network made up of 30 institutes spread over the
five continents. For more information, see

    Forward Looking Statements

    This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include financial projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions and expectations with
respect to future events, operations, products and services, and statements
regarding future performance. Forward-looking statements are generally
identified by the words "expects," "anticipates," "believes," "intends,"
"estimates," "plans" and similar expressions. Although sanofi-aventis'
management believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties,
many of which are difficult to predict and generally beyond the control of
sanofi-aventis, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include those discussed or identified in the public filings with the SEC and
the AMF made by sanofi-aventis, including those listed under "Risk Factors"
and "Cautionary Statement Regarding Forward-Looking Statements" in
sanofi-aventis' annual report on Form 20-F for the year ended December 31,
2006. Other than as required by applicable law, sanofi-aventis does not
undertake any obligation to update or revise any forward-looking information
or statements.

For further information:

For further information: Sanofi Pasteur, Pascal Barollier, Media
Relations, Tel : +33(0)4-37-37-51-41,;
Sanofi Pasteur, Len Lavenda, Media Relations US, Tel: (570) 839-4446,

Organization Profile

Sanofi Pasteur

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890